Homologous recombination deficiency, such as that mediated by BRCA1 and BRCA2 (BRCA1/2) mutations, is associated with a high risk of breast cancer and ovarian cancer (Patel et al. 2021). The gene discussed is BRCA2; the disease is breast carcinoma.